Official US documents have disclosed that a popular anti-stroke medicine may have used fictitious data while concealing research on its fatal effects. In 2009, the acclaimed British medical journal, The Lancet, published a prime story on rivaroxaban, a blood thinner medicine, which showed that the treatment was safe and efficient. But recently, the same journal warned of defaults in the trial data and claimed to initiate an investigation over it.

Lancet opens probe into ‘unreliable’ anti-stroke medicine

There are still important questions about what dose would be best, as well as the age group it will protect the most.

'Oxford-AstraZeneca vaccine safe and effective', claims Lancet report

According to preliminary results published in The Lancet journal, the COVID-19 vaccine, Sputnik V, approved by Russia last month has been shown to elicit antibody resonse with no serious adverse events in small human trials.

Russian vaccine is safe, shows no side effects: Lancet Report

lancet-report

Lancet Report, News on Lancet Report, stories on Lancet Report, articles on Lancet Report, Lancet Report stories at Wion, Lancet Report news, Lancet Report latest news

lancet report

Lancet opens probe into ‘unreliable’ anti-stroke medicine

'Oxford-AstraZeneca vaccine safe and effective', claims Lancet report

Russian vaccine is safe, shows no side effects: Lancet Report